Contribution of mammalian target of rapamycin in the pathophysiology of cirrhotic cardiomyopathy

Figure 6 Immunohistochemical staining for p-mTOR in the ventricles of the rats in the following groups: control, cirrhotic, control + rapamycin and cirrhotic + rapamycin (× 400 magnification). Human gastric tissue was used as the positive control. Note the increased immunostaining of p-mTOR in the myocytes of the rats with cirrhosis. No significant immunostaining was localized to the cardiomyocytes of the untreated cirrhotic rats. In contrast, treatment with rapamycin caused significant immunostaining in the cardiomyocytes of the cirrhotic rats. The black arrows indicate to the p-mTOR immunoblots in rat ventricles.